Induction Therapy News Today

- AbbVie will present 15 abstracts, including three oral presentations, in Crohns disease and ulcerative colitis reinforcing AbbVies commitment to advancing...

Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

A total of 136 patients were recruited in the Phase 2 trial sponsored and conducted by the French GERCOR Oncology Clinician Group, with the PRODIGE Intergroup and the supply of Tedopi® by OSE Immunotherapeutics.

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.

- CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 - Crohns disease is a chronic, systemic...

According to new research, Neuroblastoma is paediatric cancer that arises from immature nerve cells. Approximately half of the children with neuroblastoma have

/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies...

/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies...

/PRNewswire/ -- Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative...